| Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ... The Lancet Oncology 19 (4), 521-536, 2018 | 538 | 2018 |
| Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC) C Labbé, M Cabanero, GJ Korpanty, P Tomasini, MK Doherty, C Mascaux, ... Lung Cancer 111, 23-29, 2017 | 179 | 2017 |
| Uncommon EGFR mutations in advanced non-small cell lung cancer GM O’Kane, PA Bradbury, R Feld, NB Leighl, G Liu, KM Pisters, ... Lung Cancer 109, 137-144, 2017 | 150 | 2017 |
| Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR. 26): a double-blind, randomised, phase 3 trial PM Ellis, FA Shepherd, M Millward, F Perrone, L Seymour, G Liu, S Sun, ... The Lancet Oncology 15 (12), 1379-1388, 2014 | 138 | 2014 |
| Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non–Small-Cell lung cancer A Zer, MR Sung, P Walia, L Khoja, M Maganti, C Labbe, FA Shepherd, ... Clinical lung cancer 19 (5), 426-434. e1, 2018 | 124 | 2018 |
| Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials … SA Laurie, BJ Solomon, L Seymour, PM Ellis, GD Goss, FA Shepherd, ... European journal of cancer 50 (4), 706-712, 2014 | 111 | 2014 |
| Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis PA Bradbury, R Zhai, J Hopkins, MH Kulke, RS Heist, S Singh, W Zhou, ... Carcinogenesis 30 (5), 793-798, 2009 | 100 | 2009 |
| Immunotherapy for lung cancer PA Bradbury, FA Shepherd Journal of Thoracic Oncology 3 (6), S164-S170, 2008 | 98 | 2008 |
| Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes PA Bradbury, MH Kulke, RS Heist, W Zhou, C Ma, W Xu, AL Marshall, ... Pharmacogenetics and genomics 19 (8), 613-625, 2009 | 97 | 2009 |
| Genetic polymorphisms and head and neck cancer outcomes: a review J Hopkins, DW Cescon, D Tse, P Bradbury, W Xu, C Ma, P Wheatley-Price, ... Cancer Epidemiology Biomarkers & Prevention 17 (3), 490-499, 2008 | 94 | 2008 |
| Postoperative adjuvant systemic therapy in completely resected non–small-cell lung cancer: a systematic review P Bradbury, D Sivajohanathan, A Chan, S Kulkarni, Y Ung, PM Ellis Clinical lung cancer 18 (3), 259-273. e8, 2017 | 91 | 2017 |
| Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non–small cell lung cancer PA Bradbury, D Tu, L Seymour, PK Isogai, L Zhu, R Ng, N Mittmann, ... Journal of the National Cancer Institute 102 (5), 298-306, 2010 | 84 | 2010 |
| Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins TT Zhao, BG Le Francois, G Goss, K Ding, PA Bradbury, J Dimitroulakos Oncogene 29 (33), 4682-4692, 2010 | 76 | 2010 |
| Plasma transforming growth factor a and amphiregulin protein levels in NCIC Clinical Trials Group BR. 21 CL Addison, K Ding, H Zhao, A Le Maıtre, GD Goss, L Seymour, MS Tsao, ... J. Clin. Oncol 28, 5247-5256, 2010 | 75 | 2010 |
| An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib JF Hilton, D Tu, L Seymour, FA Shepherd, PA Bradbury Lung cancer 82 (1), 136-142, 2013 | 70 | 2013 |
| Design of phase I combination trials: recommendations of the clinical trial design task force of the NCI investigational drug steering committee CJ Paller, PA Bradbury, SP Ivy, L Seymour, PM LoRusso, L Baker, ... Clinical Cancer Research 20 (16), 4210-4217, 2014 | 67 | 2014 |
| Pooled analysis of the prognostic and predictive value of KRAS mutation status and mutation subtype in patients with Non–Small cell lung cancer treated with epidermal growth … A Zer, K Ding, SM Lee, GD Goss, L Seymour, PM Ellis, A Hackshaw, ... Journal of thoracic oncology 11 (3), 312-323, 2016 | 63 | 2016 |
| A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195 BJ Eigl, S North, E Winquist, D Finch, L Wood, SS Sridhar, J Powers, ... Investigational new drugs 33, 969-976, 2015 | 62 | 2015 |
| Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis PA Bradbury, R Zhai, C Ma, W Xu, J Hopkins, MJ Kulke, K Asomaning, ... Clinical cancer research 15 (14), 4680-4685, 2009 | 62 | 2009 |
| Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real … A Desilets, F Blanc-Durand, S Lau, T Hakozaki, R Kitadai, J Malo, ... European Journal of Cancer 142, 83-91, 2021 | 60 | 2021 |
